201 related articles for article (PubMed ID: 31948845)
41. Identification, synthesis, and biological evaluation of novel pyrazoles as low molecular weight luteinizing hormone receptor agonists.
Jorand-Lebrun C; Brondyk B; Lin J; Magar S; Murray R; Reddy A; Shroff H; Wands G; Weiser W; Xu Q; McKenna S; Brugger N
Bioorg Med Chem Lett; 2007 Apr; 17(7):2080-5. PubMed ID: 17321742
[TBL] [Abstract][Full Text] [Related]
42. Structure-activity relationship studies toward the discovery of selective apelin receptor agonists.
Margathe JF; Iturrioz X; Alvear-Perez R; Marsol C; Riché S; Chabane H; Tounsi N; Kuhry M; Heissler D; Hibert M; Llorens-Cortes C; Bonnet D
J Med Chem; 2014 Apr; 57(7):2908-19. PubMed ID: 24625069
[TBL] [Abstract][Full Text] [Related]
43. Apelin/APJ system as a therapeutic target in diabetes and its complications.
Hu H; He L; Li L; Chen L
Mol Genet Metab; 2016 Sep; 119(1-2):20-7. PubMed ID: 27650065
[TBL] [Abstract][Full Text] [Related]
44. Apela Regulates Fluid Homeostasis by Binding to the APJ Receptor to Activate Gi Signaling.
Deng C; Chen H; Yang N; Feng Y; Hsueh AJ
J Biol Chem; 2015 Jul; 290(30):18261-8. PubMed ID: 25995451
[TBL] [Abstract][Full Text] [Related]
45. Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo.
Read C; Yang P; Kuc RE; Nyimanu D; Williams TL; Glen RC; Holt LJ; Arulanantham H; Smart A; Davenport AP; Maguire JJ
Basic Clin Pharmacol Toxicol; 2020 Jun; 126 Suppl 6():96-103. PubMed ID: 30901161
[TBL] [Abstract][Full Text] [Related]
46. Distribution, Function, and Expression of the Apelinergic System in the Healthy and Diseased Mammalian Brain.
Ivanov MN; Stoyanov DS; Pavlov SP; Tonchev AB
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36421846
[TBL] [Abstract][Full Text] [Related]
47. Apelinergic System Structure and Function.
Shin K; Kenward C; Rainey JK
Compr Physiol; 2017 Dec; 8(1):407-450. PubMed ID: 29357134
[TBL] [Abstract][Full Text] [Related]
48. The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.
Thomas JB; Navarro H; Warner KR; Gilmour B
Bioorg Med Chem Lett; 2009 Mar; 19(5):1438-41. PubMed ID: 19195889
[TBL] [Abstract][Full Text] [Related]
49. Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists.
de Oliveira AA; Vergara A; Wang X; Vederas JC; Oudit GY
Peptides; 2022 Jan; 147():170697. PubMed ID: 34801627
[TBL] [Abstract][Full Text] [Related]
50. Structural Basis for Apelin Control of the Human Apelin Receptor.
Ma Y; Yue Y; Ma Y; Zhang Q; Zhou Q; Song Y; Shen Y; Li X; Ma X; Li C; Hanson MA; Han GW; Sickmier EA; Swaminath G; Zhao S; Stevens RC; Hu LA; Zhong W; Zhang M; Xu F
Structure; 2017 Jun; 25(6):858-866.e4. PubMed ID: 28528775
[TBL] [Abstract][Full Text] [Related]
51. Role of apelin/APJ system in hypothalamic-pituitary axis.
Yang N; Li T; Cheng J; Tuo Q; Shen J
Clin Chim Acta; 2019 Dec; 499():149-153. PubMed ID: 31525345
[TBL] [Abstract][Full Text] [Related]
52. Size-Reduced Macrocyclic Analogues of [Pyr
Tran K; Sainsily X; Côté J; Coquerel D; Couvineau P; Saibi S; Haroune L; Besserer-Offroy É; Flynn-Robitaille J; Resua Rojas M; Murza A; Longpré JM; Auger-Messier M; Lesur O; Bouvier M; Marsault É; Boudreault PL; Sarret P
J Med Chem; 2022 Jan; 65(1):531-551. PubMed ID: 34982553
[TBL] [Abstract][Full Text] [Related]
53. Structure-based design of non-hypertrophic apelin receptor modulator.
Wang WW; Ji SY; Zhang W; Zhang J; Cai C; Hu R; Zang SK; Miao L; Xu H; Chen LN; Yang Z; Guo J; Qin J; Shen DD; Liang P; Zhang Y; Zhang Y
Cell; 2024 Mar; 187(6):1460-1475.e20. PubMed ID: 38428423
[TBL] [Abstract][Full Text] [Related]
54. Expression and functional implications of the renal apelinergic system in rodents.
O'Carroll AM; Salih S; Griffiths PR; Bijabhai A; Knepper MA; Lolait SJ
PLoS One; 2017; 12(8):e0183094. PubMed ID: 28817612
[TBL] [Abstract][Full Text] [Related]
55. [The functional role of endogenous APJ agonists; Apelin and Elabela/Toddler in cardiovascular diseases].
Sato T; Kuba K
Nihon Yakurigaku Zasshi; 2019; 153(4):172-178. PubMed ID: 30971657
[TBL] [Abstract][Full Text] [Related]
56. Cooperative action of APJ and α1A-adrenergic receptor in vascular smooth muscle cells induces vasoconstriction.
Nagano K; Kwon C; Ishida J; Hashimoto T; Kim JD; Kishikawa N; Murao M; Kimura K; Kasuya Y; Kimura S; Chen YC; Tsuchimochi H; Shirai M; Pearson JT; Fukamizu A
J Biochem; 2019 Nov; 166(5):383-392. PubMed ID: 31504625
[TBL] [Abstract][Full Text] [Related]
57. Expanding the apelin receptor pharmacological toolbox using novel fluorescent ligands.
Williams TL; Macrae RGC; Kuc RE; Brown AJH; Maguire JJ; Davenport AP
Front Endocrinol (Lausanne); 2023; 14():1139121. PubMed ID: 36967803
[TBL] [Abstract][Full Text] [Related]
58. Apelin/APJ system: A novel promising target for anti-aging intervention.
Zhou Q; Chen L; Tang M; Guo Y; Li L
Clin Chim Acta; 2018 Dec; 487():233-240. PubMed ID: 30296443
[TBL] [Abstract][Full Text] [Related]
59. Biological functions of Elabela, a novel endogenous ligand of APJ receptor.
Xu J; Chen L; Jiang Z; Li L
J Cell Physiol; 2018 Sep; 233(9):6472-6482. PubMed ID: 29350399
[TBL] [Abstract][Full Text] [Related]
60. Molecular determinants on extracellular loop domains that dictate interaction between β-arrestin and human APJ receptor.
Ashokan A; Kameswaran M; Aradhyam GK
FEBS Lett; 2019 Mar; 593(6):634-643. PubMed ID: 30801688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
